flow trial semaglutide kidney outcomes Johannes Mann ending with a plug for the trial, the only dedicated renal outcome testing the effect of GLP1-RA (semaglutide) on a primary outcome of 50% decline in eGFR/ESKD/renal death # Media Centre | EASD
Description
Stopping too early can increase the chance of rebound hunger
Exclusive savings: Access member-only codes, verified reseller discounts, and insider tips
doi: 10.1038/ncomms6190
The result ranges from getting half the intended dose (ineffective, frustrating) to getting double the intended dose (nauseating, potentially dangerous)
The constipation makes sense given tirzepatides mechanism
